Bravecto topical solution for Cats

Caution:
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Description:
Each tube is formulated to provide a minimum dose of 50.0 mg (140 mg/kg) body weight. Each tube contains 280 mg of Fluralaner.

Contraindications:
A history of hepatic or renal dysfunction, or any other condition associated with hepatic or renal insufficiency, is a contraindication to the use of Bravecto.

Cats over 27.5 lb should be administered the appropriate ft.

The chemical name of fluralaner is (±)-4-[(16,4R,5R)-4-(trifluoromethyl)-4,5-dihydroxy-3,3-dimethyl-2-(2,2-dimethyl-1,3-dioxolane-4-ylidene)methyl]benzamide. Inactive ingredients: d-tocopherol, hydroxypropyl cellulose, magnesium stearate, sodium lauryl sulfate.

Animal Safety:
Marginal study: Safety study was conducted in a well-controlled field study in cats, including a total of 224 cats (with 224 tubes) and 67 with a topical active control, there were no adverse reactions.

Application site reactions have been reported in cats receiving isoxazoline drugs, with cats without a history of neurologic disorders.

Fluralaner is for systemic use and belongs to the class of neuropeptide receptor antagonists. Bravecto is a member of the targeted controlled release system. This mode of action is the inhibition of the chloride channels (gamma-aminobutyric acid and glycine) and glutamate-receptor.

For additional information about adverse drug experience reporting for fluralaner, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae

To report suspected adverse events, for technical assistance, or for general information on Bravecto, contact Intervet, Inc. (d/b/a Merck Animal Health), Madison, NJ 07940. Approved by FDA under NADA #141-459.

Fluralaner is administered topically as a single dose 2 weeks apart. After the initial application, cats should be rechecked 10 to 21 days after administration of the first dose. Following the second dose, recheck cats 21 days later. Apply Bravecto to the area of the skin behind the ear, in the interdigital cleft or in the nape of the neck. Avoid overapplying Bravecto to cats prior to first use.

If the product accidentally contacts skin, rinse with soap and water immediately after product use. If the product is swallowed, induce emesis using syrup of ipecac or 2 mL/kg of a 0.1 M sodium bicarbonate solution.

Irregularity of urination has not been evaluated.

Percentages of Cats with Adverse Reactions (AR) in the Field Study

For Cats

Cats over 27.5 lb should be administered the appropriate ft.

Clinical Pharmacology:
Fluralaner is a systemic drug and belongs to the class of neuropeptide receptor antagonists. Bravecto is a member of the targeted controlled release system. This mode of action is the inhibition of the chloride channels (GABA-A, glycine-gated chloride channels). Fluralaner is for systemic use and belongs to the class of neuropeptide receptor antagonists. Bravecto is a member of the targeted controlled release system. This mode of action is the inhibition of the chloride channels (GABA-A, glycine-gated chloride channels). Fluralaner is for systemic use and belongs to the class of neuropeptide receptor antagonists. Bravecto is a member of the targeted controlled release system. This mode of action is the inhibition of the chloride channels (GABA-A, glycine-gated chloride channels).

To report suspected adverse events, for technical assistance, or for general information on Bravecto, contact Intervet, Inc. (d/b/a Merck Animal Health), Madison, NJ 07940. Approved by FDA under NADA #141-459.

Distribution:
Intervet USA, Inc., P.O. Box 5000, Eagan, MN 55122. Approved by FDA under NADA #141-459.

For additional information about adverse drug experience reporting for fluralaner, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae

To report suspected adverse events, for technical assistance, or for general information on Bravecto, contact Intervet, Inc. (d/b/a Merck Animal Health), Madison, NJ 07940. Approved by FDA under NADA #141-459.

Distribution: Intervet USA, Inc., P.O. Box 5000, Eagan, MN 55122. Approved by FDA under NADA #141-459.

For additional information about adverse drug experience reporting for fluralaner, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae

To report suspected adverse events, for technical assistance, or for general information on Bravecto, contact Intervet, Inc. (d/b/a Merck Animal Health), Madison, NJ 07940. Approved by FDA under NADA #141-459.

Distribution: Intervet USA, Inc., P.O. Box 5000, Eagan, MN 55122. Approved by FDA under NADA #141-459.